Antengene announces xpovio® regulatory approval in hong kong for the treatment of relapsed and/or refractory multiple myeloma

Xpovio®  (selinexor) is the  first and only xpo1 inhibitor approved in hong kong xpovio®  has received regulatory approvals in 41 countries and regions  including the united states, israel, the united kingdom, the european union (the 27 member countries including france and italy), canada, norway, iceland, lichtenstein, south korea, mainland of china, taiwan china, hong kong china, singapore, australia and northern ireland. shanghai and hong kong , july 16, 2023 /prnewswire/ -- antengene corporation limited ("antengene" sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the department of health, the  government of  the hong kong special administrative region (hksar) has approved a new drug application (nda) for xpovio® (selinexor), applicable in combination with dexamethasone (xd), for the treatment of adult patients with relapsed and/or refractory multiple myeloma (r/r mm) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (pis), two immunomodulatory agents (imids), an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
KPTI Ratings Summary
KPTI Quant Ranking